Spinifex focuses on pain because it is an area of high unmet medical need. Demand for pain drugs continues to increase, fuelling the growth of a market that is expected to be worth US$50 billion annually by 2020. Neuropathic pain, where Spinifex is active, is estimated to affect 1.5 million patients worldwide and is currently poorly treated.

With a range of causes, neuropathic pain can be debilitating and a significant opportunity exists for new candidates that can deliver improved efficacy, side effect profile, time to onset and simplified dosing.

Vale Andrew Rainsford Baker (23 March 1961 – 18 March 2012)

The Spinifex Pharmaceuticals Pty Ltd (Spinifex) team wish to pay tribute to the outstanding contribution Andrew Baker made to the company's founding and ongoing success as Director and immediate past Chairman. Read more...